ClinicalTrials.gg
TerminatedNCT05716139Updated Apr 3, 2025

Natural Cycle vs Programmed Cycle Frozen Embryo Transfer

An interventional study of Natural Cycle and Artificial Cycle in Infertility, Frozen Embryo Transfer and Preeclampsia and Eclampsia, sponsored by Indira IVF Hospital Pvt Ltd. Terminated at 1 site in India. Open to female participants aged 21 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Indira IVF Hospital Pvt Ltd · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
As per institutional protocol unable to recruit adequate amount of participants

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
21 Years to 45 Years
Sex
Female
01

Study summary

The goal of this[ type of study: randomized controlled trial]is to compare Preeclampsia following Natural vs. Artificial Cycle in patients undergoing frozen embryo transfer.

The main question[s] it aims to answer is

  • Does NC-FET decreases the incidence of preeclampsia in patients undergoing frozen embryo transfer as compared to AC-FET ?

The main objective is to compare the proportion of preeclampsia in women with a viable pregnancy with natural cycle protocol to artificial cycle protocol when practicing frozen embryo transfer. Participants recruited will be divided into two ARM(1513 per arm). ARM 1 will undergo the Natural Cycle procedure of Embryo transfer, and ARM 2 will undergo the Artificial Cycle procedure of Embryo transfer. The primary outcome will be the proportion of preeclampsia. The duration of the study is around 2 year.

Read the detailed description

The Research question(PICO) addressed is Does NC-FET decreases the incidence of preeclampsia in patients undergoing frozen embryo transfer as compared to AC-FET . The hypothesis taken is NC-FET will decrease the incidence of preeclampsia compared to AC-FET. The sample size is taken as 3026 (1513 per arm). The Primary Objective is to compare the proportion of preeclampsia in women with a viable pregnancy with natural cycle protocol to artificial cycle protocol when practicing frozen embryo transfer. The study outcome of the proportion of preeclampsia after 20 weeks of gestation or 6 weeks post-delivery. There are two arms-Arm 1 Active Comparator: Natural Cycle and Arm 2 control: Artificial Cycle FET. The Randomization is done through Random Allocation as per computer generated sequence. The Blinding/masking is done Open labeled. The Study Duration is from Feb 2023 to Jan 2025. Participation Duration is 10 months.

02

Conditions studied

  • Infertility
  • Frozen Embryo Transfer
  • Preeclampsia and Eclampsia

Keywords

  • Reproduction
  • In vitro fertilization
  • Natural Frozen Embryo Transfer
  • Artificial Frozen Embryo Transfer
  • Preeclampsia
03

In context

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

This study's enrollment of 172 is above the median of 133 across 1,415 interventional studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Indira IVF Hospital Pvt Ltd is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Endometrial preparation with Hormone replacement therapy/ Natural cycle.
  • Age 21-45 years following an autologous IVF cycle (with or without preimplantation genetic testing for aneuploidy)
  • > 18 and \< 30 kg/m2
  • Endometrial thickness ≥ 7 mm after estrogen therapy or on the day of ovulation
  • Blastocyst embryo transfer

Exclusion criteria

Exclusion Criteria:

  • Uterine diseases (e.g. submucosal fibroids, polyps, previously diagnosed Müllerian abnormalities)
  • Hydrosalpinx untreated.
  • Recurrent pregnancy loss (≥ 3 previous miscarriages)
  • Recurrent implantation failure (≥ 3 previously failed embryo transfers of good-quality blastocysts)
  • Allergy to study medication
  • Pregnancy or lactation at recruitment
  • for hormonal treatment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
172 participants (actual)

Study arms

  • Active comparator
    Natural Cycle

    In this,hCG trigger and Luteal Phase Support is monitored for the natural frozen embryo cycle procedure of IVF.

    Procedure: Natural Cycle

  • Other
    Artificial Cycle

    In this, endometrial preparation and Luteal Phase Support is monitored for the artificial frozen embryo cycle procedure of IVF.

    Procedure: Artificial Cycle

Interventions

  • ProcedureNatural Cycle

    The participant will be administered a S/C injection of 250mcg r-hCG to assist ovulation and timing of the embryo transfer, when the dominant follicle reaches ≥ 18mm and serum LH \< 20 IU/L, the administration of r-hCG will be in the evening, and the embryo transfer will be scheduled seven days later (window of ± two days). The participant will begin transvaginal progesterone gel (8 %) twice daily starting 36 hrs after the trigger until ten weeks of gestation.

  • ProcedureArtificial Cycle

    Estrogen priming with oral estradiol valerate 6mg/day (2mg every 8 hours) starting from cycle D1-D5 after a first TVU. TVU will be performed 10-15 days after beginning estradiol until ET ≥ 7mm, maximum until 21 days. Patients will begin progesterone injection 100mg/day until blastocyst transfer. Frozen embryo transfer will be performed on day 6 +/- 2 days of progesterone administration. After embryo transfer, a supplementation with transvaginal progesterone gel (8 %) twice daily starting from the day of embryo transfer until ten weeks of gestation. Patients will continue Estradiol 2 mg thrice daily until 6 weeks of gestation; then dose tapering will be done to 2 mg twice daily until 9 wks of gestation. From 9th wk the estrogen dose will be tapered further to 2 mg once daily for 10 days before stopping.

06

What researchers measure

Primary outcomes

  1. proportion of preeclampsia

    The primary efficacy endpoint is the proportion of preeclampsia in women assigned to a natural cycle protocol compared to the proportion of preeclampsia in women assigned to an artificial cycle protocol.

    Time frame: after the 20th week of gestation up to six weeks postpartum

Secondary outcomes

  1. Biochemical Pregnancy Rate

    Pregnancies diagnosed only by β-human chorionic gonadotropin detection without a gestational sac visualized by vaginal ultrasound at the 6th gestational week.

    Time frame: 6 weeks after Embryo Transfer

  2. Implantation Rate

    The number of gestational sacs observed by transvaginal ultrasound at the 6th gestational week per the number of embryos transferred.

    Time frame: 4 weeks +2 weeks after ET

  3. Clinical Pregnancy Rate

    Detection of a foetal heartbeat on transvaginal ultrasound at the 6th gestational week per embryo transfer cycle.

    Time frame: 4 weeks +2 weeks after ET

  4. Ongoing Pregnancy Rate

    Presence of gestational sacs with a heartbeat at the 12th gestational week per embryo transfer cycle.

    Time frame: 12 weeks after embryo Transfer

  5. Live Birth Rate

    The number of deliveries that resulted in at least one live birth per 100 Embryo transferred cycle.

    Time frame: 28 weeks(+12 weeks) after embryo transfer

  6. Miscarriage Rate

    Number of spontaneous pregnancy losses in which a gestational sac/s was previously observed (before 20th gestational weeks) per 100 clinical pregnancy.

    Time frame: Within 20 weeks of gestation

  7. Preterm birth

    Preterm is defined as babies born alive before 37 weeks of pregnancy are completed

    Time frame: < 37 weeks

  8. Extreme preterm birth

    Extreme Preterm is defined as babies born alive before 28 weeks of pregnancy

    Time frame: 20-28 weeks

  9. Fetal growth restriction

    Fetal growth restriction (FGR) is most often defined as an estimated fetal weight less than the 10th percentile for gestational age by prenatal ultrasound evaluation

    Time frame: 20-40 weeks of gestation

  10. Fetal birthweight

    Is defined as the weight of baby just after birth

    Time frame: within 30 minutes of birth

  11. Premature detachment of normally inserted placenta

    It is defined as a premature separation of the placenta before delivery.

    Time frame: 12 weeks of GA till labor

  12. Maternal hypertension

    It is defined as blood pressure more than 140/90 mm Hg detected first time after 20 weeks of gestation till 6 weeks of postpartum without proteinuria

    Time frame: After 20 weeks of GA till 6 weeks postpartum

  13. Eclampsia

    Eclampsia is defined as the new onset of generalized tonic-clonic seizures in a woman with preeclampsia.

    Time frame: After 20 weeks of GA till 6 weeks postpartum

  14. HELLP Syndrome

    It is defined as hemodialysis, elevated liver enzymes, and low platelet count

    Time frame: After 20 weeks of GA till 6 weeks postpartum

  15. Maternal mortality

    Maternal death is defined as pregnancy or its management (excluding accidental or incidental causes) during pregnancy and childbirth or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy

    Time frame: from start of pregnancy to 42 weeks of pregnancy

  16. Fetal death

    Fetal death refers to the spontaneous intrauterine death of a fetus after 20 weeks of GA before delivery

    Time frame: 20 weeks of GA before delivery

  17. Frequency of adverse events

    An adverse event (AE) is any untoward medical occurrence in a patient.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • Indira IVF Hospital Private Limited
    Udaipur, Rajasthan 313001, India
08

References and documents

Publications

  • American College of Obstetricians and Gynecologists' Committee on Obstetric Practice; Committee on Genetics; U.S. Food and Drug Administration. Committee Opinion No 671: Perinatal Risks Associated With Assisted Reproductive Technology. Obstet Gynecol. 2016 Sep;128(3):e61-8. doi: 10.1097/AOG.0000000000001643. PubMed 27548556 ↗
  • Baksh S, Casper A, Christianson MS, Devine K, Doody KJ, Ehrhardt S, Hansen KR, Lathi RB, Timbo F, Usadi R, Vitek W, Shade DM, Segars J, Baker VL; NatPro Study Group. Natural vs. programmed cycles for frozen embryo transfer: study protocol for an investigator-initiated, randomized, controlled, multicenter clinical trial. Trials. 2021 Sep 27;22(1):660. doi: 10.1186/s13063-021-05637-3. PubMed 34579768 ↗
  • Busnelli A, Schirripa I, Fedele F, Bulfoni A, Levi-Setti PE. Obstetric and perinatal outcomes following programmed compared to natural frozen-thawed embryo transfer cycles: a systematic review and meta-analysis. Hum Reprod. 2022 Jun 30;37(7):1619-1641. doi: 10.1093/humrep/deac073. PubMed 35553678 ↗
  • Devroey P, Polyzos NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod. 2011 Oct;26(10):2593-7. doi: 10.1093/humrep/der251. Epub 2011 Aug 9. PubMed 21828116 ↗
  • Ginstrom Ernstad E, Wennerholm UB, Khatibi A, Petzold M, Bergh C. Neonatal and maternal outcome after frozen embryo transfer: Increased risks in programmed cycles. Am J Obstet Gynecol. 2019 Aug;221(2):126.e1-126.e18. doi: 10.1016/j.ajog.2019.03.010. Epub 2019 Mar 22. PubMed 30910545 ↗
  • Kawwass JF, Badell ML. Maternal and Fetal Risk Associated With Assisted Reproductive Technology. Obstet Gynecol. 2018 Sep;132(3):763-772. doi: 10.1097/AOG.0000000000002786. PubMed 30095760 ↗
  • Lee JC, Badell ML, Kawwass JF. The impact of endometrial preparation for frozen embryo transfer on maternal and neonatal outcomes: a review. Reprod Biol Endocrinol. 2022 Feb 28;20(1):40. doi: 10.1186/s12958-021-00869-z. PubMed 35227270 ↗
  • Luke B. Pregnancy and birth outcomes in couples with infertility with and without assisted reproductive technology: with an emphasis on US population-based studies. Am J Obstet Gynecol. 2017 Sep;217(3):270-281. doi: 10.1016/j.ajog.2017.03.012. Epub 2017 Mar 18. PubMed 28322775 ↗
  • Malik A, Jee B, Gupta SK. Preeclampsia: Disease biology and burden, its management strategies with reference to India. Pregnancy Hypertens. 2019 Jan;15:23-31. doi: 10.1016/j.preghy.2018.10.011. Epub 2018 Nov 2. PubMed 30825923 ↗
  • Rienzi L, Gracia C, Maggiulli R, LaBarbera AR, Kaser DJ, Ubaldi FM, Vanderpoel S, Racowsky C. Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update. 2017 Mar 1;23(2):139-155. doi: 10.1093/humupd/dmw038. PubMed 27827818 ↗
  • von Versen-Hoynck F, Schaub AM, Chi YY, Chiu KH, Liu J, Lingis M, Stan Williams R, Rhoton-Vlasak A, Nichols WW, Fleischmann RR, Zhang W, Winn VD, Segal MS, Conrad KP, Baker VL. Increased Preeclampsia Risk and Reduced Aortic Compliance With In Vitro Fertilization Cycles in the Absence of a Corpus Luteum. Hypertension. 2019 Mar;73(3):640-649. doi: 10.1161/HYPERTENSIONAHA.118.12043. PubMed 30636552 ↗
  • Chen JZ, Sheehan PM, Brennecke SP, Keogh RJ. Vessel remodelling, pregnancy hormones and extravillous trophoblast function. Mol Cell Endocrinol. 2012 Feb 26;349(2):138-44. doi: 10.1016/j.mce.2011.10.014. Epub 2011 Oct 25. PubMed 22051447 ↗
  • Shi Y, Sun Y, Hao C, Zhang H, Wei D, Zhang Y, Zhu Y, Deng X, Qi X, Li H, Ma X, Ren H, Wang Y, Zhang D, Wang B, Liu F, Wu Q, Wang Z, Bai H, Li Y, Zhou Y, Sun M, Liu H, Li J, Zhang L, Chen X, Zhang S, Sun X, Legro RS, Chen ZJ. Transfer of Fresh versus Frozen Embryos in Ovulatory Women. N Engl J Med. 2018 Jan 11;378(2):126-136. doi: 10.1056/NEJMoa1705334. PubMed 29320646 ↗

Individual participant data

Plan to share: Yes — IPD will be shared with other researchers after publication of primary results.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: After six months of publication of primary results statistical plan and ICF

Access criteria: IPD will be shared on request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Mar 2024, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2023
First posted
Feb 8, 2023
StartActual
Jul 15, 2023
Primary completionActual
Mar 26, 2024
CompletionActual
Mar 26, 2024
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05716139
Lead sponsor
Indira IVF Hospital Pvt Ltd
Responsible party
Sponsor
First posted
Feb 8, 2023
Start date
Jul 15, 2023
Primary completion
Mar 26, 2024
Completion
Mar 26, 2024
Last update
Apr 3, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion